The International Contrast Ultrasound Society (ICUS)

Echo Research and Practice



Echo Research and Practice

Echo Research and Practice is a new, international journal of the British Society of Echocardiography, and is the first open access journal in echocardiography.  Topics include original cardiac ultrasound research, critical reviews, selected case reports, videos and educational materials.  Publication fees are discounted 10% for members of ICUS.

Click here to learn more:

Bracco Diagnostics has received approval for its Lumason ultrasound contrast agent, which now joins Definity (Lantheus Medical Imaging) and Optison (GE Healthcare) as approved ultrasound contrast agents in the U.S. Known previously as SonoVue, Lumason (sulfur hexafluoride lipid microbubbles) is indicated for patients whose echocardiography images are hard to see with ultrasound, according to the FDA.

Click here for full FDA statement:

Left Ventricular Opacity Software Now Standard on GE Healthcare’s Vivid E9
As of  Jan 1, 2014, the Vivid E9 XDclear and BT12 consoles include left ventricular opacity (LVO) Contrast in the standard base configuration.
The Vivid E9 is GE Healthcare’s leadership cardiovascular ultrasound system designed for cardiac 4D and 2D imaging, with additional capabilities that include pediatric, fetal/obstetrics, peripheral vascular, and transesophageal applications. GE Healthcare believes that inclusion of LVO contrast as part of the Vivid E9 standard configuration could lead to greater adoption of contrast usage into echocardiographic studies.
To read the full release, click here.

We welcome our newest board member, Dr Ed Grant, representing the USA and Body Imaging.  Ed has been an enthusiastic supporter of CEUS for many years and has performed several clinical studies both off label and more recently, as part of the Bracco multi-centre study for characterization of focal liver lesions, performed in the USA.

Ed is a Professor and Chairman of the Department  of Radiology at USC's Keck School of Medicine, Los Angeles, CA.

On November 18, 2013, GE Healthcare announced that it received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ─ an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the US and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the US.
Click here to see full release

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:






ICUS Tweets

Detect liver cancer effectively and more cheaply, without harmful radiation imaging or costly MRI eqpt. Read more:
Lose weight while you sleep? Maybe soon! Read more at:
Follow Bubble Conference 2016 comment at #bubble2016

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS News